Pre-IPO investment is unprofitable, early-stage financing has doubled, computer biology investment has tripled in one year, 2021 European and American biopharmaceutical investment and financing summary

In 2021, the investment and financing trend in the biopharmaceutical field in Europe and the United States seems to be similar to that in China, and they are all inclined to early-stage investment
.

Previously, E-pharmaceutical managers learned from a number of domestic industry investors that in 2021, more biopharmaceutical investment institutions will begin to use "investing early and investing in small" as a layout strategy
.

Recently, SPD Silicon Valley Bank released the report "Trends of Investment and Exit in the Healthcare Industry".

01 Large-scale IPOs in the first half of the year, but dare not invest in pre-IPOs in the second half of the year

Specifically, the stock price performance of companies listed in 2019 and 2020 was relatively strong, but the stock price performance of companies listed in 2021 was not satisfactory, thus affecting the financing of quasi-listed companies
.

Since the first quarter of 2021, the number of quasi-public company financing deals has declined in each quarter, while the number of private companies completing mezzanine financing has continued to increase

It is worth noting that the investment and financing situation of biopharmaceuticals in Europe and the United States seems to be similar to that in China
.

According to the statistics of E-pharmaceutical managers, from October 1, 2020 to September 30, 2021, the largest number of financings occurred in angel rounds, with 568 rounds, followed by rounds A, B and preA rounds, with a total of thousands of rounds.

In terms of indications, platform companies are the most popular.
According to Silicon Valley Bank statistics, the transaction volume of seed rounds/A rounds of such companies has ranked first for two consecutive years
.

Oncology also consistently ranks second

In addition, deals in new technology areas such as CAR-T cell therapy and CRISPR have attracted much attention
.

Silicon Valley Bank observed a number of early-stage pharmaceutical companies adopting a "hub-and-spoke" model, with financing available to multiple companies across multiple technology paths

Of the nine companies to be acquired in 2021, three were acquired with a combined transaction value of more than $1 billion
.

Vividion Therapeutics (acquired by Bayer), Teneobio (acquired by Amgen) and Amunix (acquired by Sanofi)

However, companies in the early stages of research and development are also the "prey" that large pharmaceutical companies are looking for.
At the previous JP Morgan conference, a number of large multinational pharmaceutical companies announced their future mergers and acquisitions plans.
Some MNC expects to spend 50 billion in the next three years US dollars to expand the pipeline
.

Silicon Valley Bank also expects mergers and acquisitions in 2022 to be brisk and likely to be dominated by large acquirers looking for public companies with depressed valuations

02 Computer biology tripled

Computational biology companies need to meet the following four conditions:

Specialize in drug discovery or development (biopharmaceuticals/R&D tools);

Apply new computational tools to obtain biochemical research results;

have the ability or potential to create a platform;

Have a team with experience in developing algorithms
.

Among the 707 biopharmaceutical and R&D tool companies that have completed seed round/round A financing for the first time since 2019, 129 are computational biology companies, accounting for 18%
.

Investments in computational biology companies surged in 2021, nearly double the amount raised in 2019 and 2020 combined